ReviewFrontiers in medicine2026
Biomarkers of multi-organ dysfunction in ECMO: prognostic signposts for palliative transitions.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consistently high lactate levels and poor clearance on ECMO are important early signs of poor perfusion and useless care. For example, lactate levels over 8 mmol/L at 12 h, staying above 2.5 mmol/L at 24 h, or clearance rates below 22% are all strong signs that a patient will die in the hospital. Beyond metabolic markers, signs of specific organ failure are grave prognostic factors. Total bilirubin is a better way to check for liver problems than enzymes. A peak bilirubin level of more than 15 mg/dL means that the liver is not clearing the bilirubin properly and increases the risk of death by four times. Acute kidney injury requiring renal replacement therapy (CRRT) reflects severe multi-organ failure and is independently associated with mortality rates of 60-80%. Systemic coagulopathy also marks clinical decline, with an overt DIC score ≥5 or a precipitous ≥50% drop in platelets on the first day carrying an 8-9-fold increased risk of death. Furthermore, a profound inflammatory response, evidenced by high interleukin-6 and procalcitonin levels (≥0.5 μg/L), correlates with refractory shock and significantly worse outcomes compared to nonspecific markers like CRP. Ultimately, the persistence of these metabolic, hepatic, renal, and inflammatory abnormalities suggests irreversible organ damage and a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.